Severe Legionellosis Cases Admitted to Grenoble University Hospital, 2006-2011.
NCT ID: NCT02884700
Last Updated: 2016-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
82 participants
OBSERVATIONAL
2009-09-30
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Legionella PCR Techniques for the Routine Diagnosis of Legionellosis
NCT00452153
Nosocomial and Community Acquired Legionella Pneumophila Pneumonia.
NCT04106037
Nosocomial Influenza Surveillance of 2022 - 2027 Seasonal Period
NCT05712759
Study of Symptoms Linked to Covid-19 in Residents and Professionals in EHPAD, Associated With a Dual Diagnostic Approach by PCR and Serology: a Cohort in Île-de-France.
NCT04677283
Clinical Impact of 16S rDNA PCR
NCT03915275
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Clinical, epidemiological, diagnostic and prognostic data of these patients were recorded retrospectively.
Lower respiratory samples collected from these patients on a routine basis for microbiological analysis, especially Legionella culture, were tested using traditional microbiological methods. The remaining part of these samples was stored at -80°C fur further molecular analyses.
The molecular tools developed by our bacteriology laboratory included the following: a real-time polymerase chain reaction (qPCR) test allowing detection and differentiation of L. pneumophila and other Legionella species; a qPCR test allowing determination of the Legionella DNA load in lower respiratory samples; a qPCR allowing detection of gyrA (the gene encoding subunit A of DNA gyrase) mutations that the investigators previously determined to be correlated with fluoroquinolones resistance in L. pneumophila; a high-throughput sequencing approach allowing confirmation of gyrA mutations and determination of the percentage of mutated alleles.
The microbiological data, especially those obtained with the developped molecular tools, were tentatively correlated with the severity and outcome of infection in our patients' cohort.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Severe legionellosis cases
Patients admitted to Grenoble University Hospital for severe legionellosis between 2006 and 2011.
Real-time PCR testing of lower respiratory tract samples
qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Real-time PCR testing of lower respiratory tract samples
qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* proven legionellosis case (positive culture and/or PCR and/or urinary antigen test)
* severe case requiring hospitalization
Exclusion Criteria
* pregnant women
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AdministrateurDRC
Pr. Max Maurin
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hélène Sabbah-Guillaume, Director
Role: STUDY_DIRECTOR
Direction of Research and Medical Innovation (DRCI)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Grenobole University Hospital
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.